HTBX News Alert Heat Biologics Inc (HTBX) 4.18 12/25/2014 09

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Heat Biologics Inc (HTBX) 4.18 $HTBX

Heat Biologics, Inc. Expands Product Development Team to Support Development of Lead Product Candidates in Oncology
GlobeNewswire - Tue Dec 02, 7:00AM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced the expansion of its product development team. Three new director-level team members have joined Heat to help execute its Phase 2 strategy and prepare for Phase 3 delivery. The new hires will assume responsibility for Manufacturing, Regulatory Affairs and Quality Assurance, and Clinical Operations under the direction of Dr. Melissa Price, VP of Clinical and Regulatory Affairs.
HTBX: 4.18 (-0.22)

Heat Biologics, Inc. to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2 in New York
GlobeNewswire - Mon Dec 01, 7:01AM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that Jeff Wolf, CEO, will present a corporate update at the 26 Annual Piper Jaffray Healthcare Conference, taking place at the New York Palace Hotel, December 2-3, 2014.
HTBX: 4.18 (-0.22)

Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST

HTBX: 4.18 (-0.22), BIB: 122.51 (+3.83), INCY: 71.57 (+1.99), PFE: 31.42 (-0.03), IBB: 299.80 (+5.12), DRGS: 53.60 (unch), BIND: 5.73 (+0.06), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), ONTY: 1.89 (+0.01), ECYT: 6.33 (+0.24), BIS: 47.26 (-1.74), CLVS: 54.58 (+0.43), AZN: 70.44 (+0.26), MRK: 57.46 (+0.25), ARIA: 6.81 (+0.15), IRY: 47.28 (-0.01), IXJ: 100.54 (+0.55), FPRX: 26.12 (+0.07)

Heat Biologics Q3 results
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:07AM CST

HTBX: 4.18 (-0.22)

Heat Biologics misses by $0.04
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 6:35AM CST

HTBX: 4.18 (-0.22)

Heat Biologics, Inc. Reports 2014 Third Quarter Financial Results
GlobeNewswire - Fri Nov 14, 6:30AM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today its financial results for the third quarter ended September 30, 2014 and outlined key highlights of its lead clinical development programs.
HTBX: 4.18 (-0.22)

Nasdaq stocks posting largest percentage decreases
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
HTBX: 4.18 (-0.22), TNGO: 12.98 (unch), ENPH: 14.38 (-0.02), PRSC: 37.50 (+0.70), MTRX: 21.75 (-0.05), EPZM: 17.71 (+0.01), CHUY: 19.28 (-0.19), AMRI: 15.19 (+0.05), ANDE: 55.10 (+0.35), SNMX: 5.95 (+0.34), ZU: 23.81 (+0.25)

Heat Biologics Takes a New Approach to Immunotherapy
ACCESSWIRE - Mon Nov 03, 1:01PM CST
WHITEFISH, MT / ACCESSWIRE / November 3, 2014 / Immunotherapy leverages the body's own immune system to fight off diseases ranging from allergies to cancer. For example, Dendreon Corporation's (NASDAQ: DNDN) PROVENGE therapy takes the patient's own immune cells and reprograms them to attack advanced prostate cancer. These dynamics led to a 22.5% reduced risk of death with just a 1.5% discontinuance rate.
HTBX: 4.18 (-0.22), DNDN: 0.13 (-0.02), NLNK: 39.08 (+1.36), GALE: 1.49 (-0.02)

Heat Biologics starts patient dosing in bladder cancer trial
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 12:07PM CDT

HTBX: 4.18 (-0.22)

Heat Biologics, Inc. Commences Patient Dosing of Phase 2 Clinical Study of Vesigenurtacel-L for the Treatment of Bladder Cancer
GlobeNewswire - Mon Oct 27, 7:05AM CDT
Heat Biologics, Inc. (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today that it has initiated patient dosing in its Phase 2 clinical trial of vesigenurtacel-L (HS-410) in subjects with high-risk, non-muscle invasive bladder cancer. Vesigenurtacel-L is Heat's investigational drug in a series of proprietary Immune Pan Antigen Cytotoxic Therapy ("ImPACT" based allogeneic cell lines designed to direct killer T cells to attack cancer. The primary endpoint for the Phase 2 portion of the bladder cancer study is one-year disease-free survival.
HTBX: 4.18 (-0.22)

Heat Biologics Completes Dosing for Vesigenurtacel-L Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 2:54PM CDT
Heat Biologics, Inc. (HTBX) recently announced that it has dosed the ninth and final patient required for the phase I part of its phase I/II clinical study on experimental biologic candidate, vesigenurtacel-L (HS-410).
HTBX: 4.18 (-0.22), SHPG: 209.29 (+0.07), SCMP: 13.75 (+0.44), PCRX: 92.09 (-1.79)

Heat Biologics, Inc. Completes Enrollment of Phase 1 Clinical Trial of Vesigenurtacel-L for the Treatment of Bladder Cancer Required to Advance to Phase 2
GlobeNewswire - Thu Oct 02, 6:35AM CDT
Heat Biologics, Inc. (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today that it has dosed the ninth and final patient required in the Phase 1 portion of its Phase 1/2 clinical study for Vesigenurtacel-L (HS-410) in patients with high-risk non-muscle invasive bladder cancer. The Company expects to commence the Phase 2 portion of the bladder cancer clinical trial during the fourth quarter of 2014.
HTBX: 4.18 (-0.22)

Heat Biologics, Inc. to Present at the 13th Annual BIO Investor Forum in San Francisco on Tuesday, October 7, 2014
GlobeNewswire - Tue Sep 30, 6:30AM CDT
Heat Biologics, Inc. (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting at the 13 Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will be held October 7-8, 2014 at the Palace Hotel in San Francisco, California.
HTBX: 4.18 (-0.22)

Heat Biologics Commences Patient Dosing in Phase 2 Study of Viagenpumatucel-L for the Treatment of Non-Small Cell Lung Cancer
GlobeNewswire - Thu Sep 18, 7:07AM CDT
Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company" (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today that it has initiated dosing in its Phase 2 trial of Viagenpumatucel-L (HS-110) in patients with non-small cell lung cancer ("NSCLC" . HS-110 is Heat's most advanced product candidate in a series of proprietary Immune Pan Antigen Cytotoxic Therapy ("ImPACT" based allogeneic cell lines designed to direct killer T cells to attack cancer. Roger B. Cohen, M.D., Professor of Medicine at the University of Pennsylvania and Associate Director for Clinical Research for the Abramson Cancer Center is Lead Investigator of the Phase 2 trial.
HTBX: 4.18 (-0.22)

Heat Biologics, Inc. to Present and Webcast at Two Investor Conferences in September
GlobeNewswire - Thu Sep 04, 6:30AM CDT
- Rodman & Renshaw 16 Annual Global Investment Presentation on September 9, 2014 -
HTBX: 4.18 (-0.22)

Heat Biologics concludes up to USD7.5m secured term loan facility with Square 1 Bank
M2 - Tue Aug 26, 7:48AM CDT
Biopharmaceutical company Heat Biologics (NasdaqCM:HTBX) announced on Monday that it has completed a debt financing of up to USD7.5m with Square 1 Bank in four tranches based on the achievement of significant corporate milestones over the next 14 months.
HTBX: 4.18 (-0.22)

Heat Biologics, Inc. Closes on Up to $7.5 Million Secured Term Loan Facility
GlobeNewswire - Mon Aug 25, 7:29AM CDT
Heat Biologics, Inc. (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today that it closed on a debt financing in the principal amount of up to $7.5 million with Square 1 Bank. Funds from the secured term loan will be utilized for working capital and to progress the Company's clinical trials and will be made available to the Company in four tranches based on the achievement of significant corporate milestones over the next 14 months. Following the closing of the loan, management expects the Company's current cash position to be extended by at least two quarters through the first quarter of 2016.
HTBX: 4.18 (-0.22)

Heat Biologics, Inc. Reports 2014 Second Quarter Financial Results
GlobeNewswire - Thu Aug 14, 6:05AM CDT
Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company" (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today its financial results for the second quarter ended June 30, 2014 and outlined key highlights of its lead clinical development programs.
HTBX: 4.18 (-0.22)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 120

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 107

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 128

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 119

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Cloud Security’s $26.8 Billion Test Is All About Execution

Updated Category News Views 65

A cloud dashboard that spits out ten thousand alerts is not protection; it is an expensive way to make a security team miserable. That frustration sits right in the middle of Frost & Sullivan’s projection that global cloud security revenue will climb from $8.4 billion in 2025 to $26.8 billion by 2031, a 21.4% compound annual growth rate. The number is hefty, no...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 82

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 90

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading

Top 5 Most Recently Viewed Articles

Aluminum Design Fumble: Geometry Over Wall Thickness

Updated Category News Views 420

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Continue Reading
BW LPG Limited Welcomes BW Chinook: A Significant Milestone

Updated Category News Views 180

Significant Acquisition by BW LPG Limited BW LPG Limited has recently taken a remarkable step in enhancing its fleet and operational capabilities. The company announced the acquisition of the vessel BW Chinook, marking an important milestone in its ongoing strategy to strengthen its position in the global LPG market. Details of the Vessel Delivery Following a stock...

Continue Reading
COMAC's Expansion: New Hong Kong Office and Maintenance Deal

Updated Category News Views 175

COMAC's Global Expansion Efforts Chinese planemaker COMAC has taken a significant step in its quest to enter the global passenger jet market by inaugurating its second international office in Hong Kong. This move aligns with their strategy to provide enhanced services and establish a stronger footprint outside mainland China. The opening not only symbolizes growth but...

Continue Reading
Torrid Holdings CEO Lisa Harper Makes Strategic Stock Move

Updated Category News Views 415

Lisa Harper's Recent Sale of Company Shares Lisa Harper, the CEO of Torrid Holdings Inc. (NYSE: CURV), has recently sold shares worth $283,909, according to a filing with the Securities and Exchange Commission. In this transaction, she sold 74,713 shares at a price of $3.80 each. This sale is part of her exercise of the underwriters' option to purchase additional shares...

Continue Reading
Getty Images Plans Q3 2024 Financial Results Release Date

Updated Category News Views 102

Getty Images Announces Q3 2024 Financial Results Date Getty Images Holdings, Inc. (NYSE: GETY), a leader in the global visual content industry, is gearing up to share its financial results for the third quarter of 2024. The results will be unveiled right after market closing on November 7, 2024. This announcement signals an important moment for stakeholders keeping a...

Continue Reading